Development Cost. 11.1 Development Cost of the Product in accordance with this Agreement shall be the relevant amount set out in Schedule 1 payable to the Developer by the Publisher in accordance with the Milestone Payment Schedule detailed in Schedule 1.
11.2 Without prejudice to the provisions of paragraph 4 above, Publisher shall use reasonable endeavors to expedite its acceptance of deliverables in relation to a Milestone.
11.3 Developer may raise an invoice on the Publisher upon notice by the Publisher of its acceptance of each Milestone pursuant to Paragraph 4 and such invoice is due within ten (10) calendar days of this acceptance.
11.4 The Publisher shall have no obligation to make any payments to the Developer under this Agreement for anything save for the payment of the Development Cost referred to in this paragraph 11, Profits under paragraph 10 and payments (if relevant) under paragraph 9. Nevertheless, any other additional payments that the Publisher, in its discretion, makes to the Developer in relation to the Developer’s work under this Agreement for any reason shall be treated as a further Development Cost payment and fully recoupable from Profits payable under this Agreement, unless otherwise agreed in writing.
11.5 All Development Costs paid by Publisher to the Developer together with payments (if relevant) under paragraph 9 (except payment of Profits) shall be recoupable at the rate of 100% out of the cash received by Publisher for sale and license of the Product.
11.6 The parties agree that no finder’s fees are payable to any party under this transaction.
Development Cost. An amount of Rs. NIL is payable towards Development Cost.
Development Cost. For clarification, it is approved possibility that Development Cost can occur within Exploration Period and Exploration Cost within Development Period.
Development Cost. Hansoh shall bear (i) all costs and expenses in respect of the Development of the Licensed Product for the NMOSD indication, the Viela LCM Indications, and Hansoh Selected Indications in the Territory, including the Fully Burdened Costs of the Licensed Products used for such Development; provided that the costs and expenses for any Global Study for the Licensed Product for a Viela LCM Indication will be calculated in accordance with Section 3.1(b)(ii); and (ii) any and all costs and fees associated with applying for and obtaining Regulatory Approval in the Territory for the Licensed Products. Viela may invoice Hansoh on a [***] for the costs incurred by Viela or Designee, and Hansoh shall pay the amount invoiced within [***] ([***]) [***] after the receipt of any such invoice.
Development Cost. Ji Xing shall be solely responsible for all the costs and expenses to Develop the Product in the Territory.
Development Cost. NK shall be solely responsible for all costs for Development and Commercialization of IL13 and/or Product in the Territory, including, but not limited to, any costs associated with pre-clinical studies and clinical studies, any other studies or research projects and all in-house studies with the exception, however, that any IL13 (if requested by NK, in the form of a pharmaceutical preparation in vials and with labels, which labels shall be furnished by NK to NeoPharm) reasonably required by NK to conduct its pre-clinical studies, if any, Phase I Study and Phase II Study shall be provided by NeoPharm at NeoPharm’s cost.
Development Cost. (Confidential material redacted and filed separately with the Commission)
a. Invoice will be submitted by Aug. 24, 1999
b. 1st half shall be paid within two weeks upon receipt of the invoice.
c. 2nd half shall be paid immediately upon approval on T/P sample.
Development Cost. (a) Committed Studies As Of The Effective Date (Current Budget). Except as set forth in Section 4.5(b) below, Exelixis shall bear one hundred percent (100%) of all Development Costs for the first [ * ] dollars ($[ * ]) of Development Costs for all Clinical Trials that are committed studies in the GDP [ * ] as of the Effective Date (“Initial Committed Studies”). Thereafter, except as set forth in Section 4.5(b) below, (i) Exelixis shall bear sixty-five percent (65%) and Licensee shall bear thirty-five percent (35%) of all Development Costs for such Clinical Trials [ * ] until the aggregate Development Costs of such Clinical Trials equals [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. [ * ] dollars ($[ * ]), and (ii) if aggregate Development Costs for such Clinical Trials [ * ] exceed [ * ] dollars ($[ * ]), Exelixis shall bear [ * ] percent ([ * ]%) and Licensee shall bear [ * ] percent ([ * ]%) of all remaining Development Costs for such Clinical Trials. For Clinical Trials that become committed studies in the GDP after the Effective Date, Exelixis shall bear sixty-five percent (65%) and Licensee shall bear thirty-five percent (35%) of all Development Costs of such Clinical Trials. If Exelixis completes the Initial Committed Studies for an amount less than [ * ] dollars ($[ * ]), any amount not spent (“Excess Funds”) shall be credited against the Parties’ respective share of Clinical Trials that become committed studies in the GDP after the Effective Date. Without limiting the foregoing, if any [ * ].
Development Cost. 10.1 The Landowner shall transfer for the purpose of constructing and operating the pop-up residences (the “Development cost”) the amount of USD 150,000.00 (one hundred fifty thousand US dollars ) to Poshtel or Poshtel affiliate bank account not later than 10 days upon the Commencement date of this Agreement
10.2 Poshtel shall have the sole authorization on the Investment bank account and it may not use the bank account for any other purposes. The Landowner shall be provided with bank statements upon written request without undue delay.
10.3 The Investment shall be used for the construction of the pop-up residences and the subsequent operation of the pop-up residences on the Land, and the Landowner shall have no right of refund to the Development cost.
Development Cost. 3.1 For development of the Phoenix 2 and LMX 2 products, Silan shall pay directly to ESS or to third party engineering and fabrication companies all costs incurred in the development of the Phoenix 2 and LMX 2 products, including but not limited to all mask charges, packaging and engineering wafer lots, all development and test boards, all further engineering costs and expenses incurred by ESS, and all wafer, fabrication and packaging expenses. All such costs must have prior written approval from Silan. **** Confidential Treatment Requested. 5
3.2 The parties contemplate that following the Effective Date of this Agreement, ESS shall provide Silan with the opportunity to hire current ESS employees who are currently employed by ESS and who have specializations in ESS’s DVD line of business. No such employee shall be obligated to join Silan, but Silan and ESS shall work together to persuade such employees to accept employment with Silan.
